{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:14:09Z","timestamp":1782472449559,"version":"3.54.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:p>\n                    The study is to assess the accuracy and convenience of utilizing the \u201cFeiChangHeHu\u201d mini-program in predicting the risk of chemotherapy-induced nausea and vomiting (CINV), evaluating the prevalence and severity symptom related to CINV, and determining the temporal patterns of symptoms. A single-center, retrospective study was conducted at the Thoracic Oncology Department, TongJi Hospital, TongJi Medical College of Huazhong University of Science and Technology from April 24 to June 18, 2024. Eighty-seven adult lung cancer patients undergoing chemotherapy used the \u201cFeiChangHeHu\u201d mini-program to report symptoms daily. The platform integrated automated CINV risk stratification, symptom tracking, clinical alerts, and intervention for grade \u22652 symptoms. Data were collected prospectively and analyzed using descriptive statistics and inferential statistics, including chi-square tests and\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    tests by SPSS 26.0 (IBM Corporation, Armonk). The receiver operating characteristic curve and the area under the curve were used to quantify the ability of the model to distinguish risks. The moderate-to-high risk detection rate was 98.85% by mini-program. The model showed moderate performance with an area under the curve of 0.712 (95% confidence interval: 0.611\u20130.852), indicating acceptable classification accuracy. Nausea was the most prevalent toxicity, affecting 59.77% of patients, with 88% classified as grades 3 to 4. The temporal distribution of chemotherapy-induced adverse events exhibits distinct peaks across different symptoms. Nurses resolved 100% of alerts within 24 hours, and no severe CINV-related complications were reported during the study period. The \u201cFeiChangHeHu\u201d mini-program improves CINV risk detection and symptom monitoring in lung cancer patients. Future studies should explore scalability and artificial intelligence-driven predictive analytics.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047389","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:02:34Z","timestamp":1769965354000},"page":"e47389","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of the \u201cFeiChangHeHu\u201d WeChat mini-program for real-time management of chemotherapy-induced nausea and vomiting in lung cancer patients"],"prefix":"10.1097","volume":"105","author":[{"given":"Fan","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9282-9497","authenticated-orcid":false,"given":"Xiaoguang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People\u2019s Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260519","first-page":"100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends.","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"104444","DOI":"10.1016\/j.critrevonc.2024.104444","article-title":"Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: the road to success.","volume":"201","author":"Belluomini","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.3390\/ijms231911267","article-title":"Efficacy and safety of ginger on the side effects of chemotherapy in breast cancer patients: systematic review and meta-analysis.","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R4-20260519","first-page":"87","article-title":"ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients.","volume":"27","author":"Razvi","year":"2019","journal-title":"Support Care Cancer"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fphar.2020.00329","article-title":"Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review.","volume":"11","author":"Mosa","year":"2020","journal-title":"Front Pharmacol"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1007\/s11136-022-03093-3","article-title":"A PRO-cision medicine intervention to personalize cancer care using patient-reported outcomes: intervention development and feasibility-testing.","volume":"31","author":"Snyder","year":"2022","journal-title":"Qual Life Res"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"e1303","DOI":"10.1200\/OP.20.00639","article-title":"Chemotherapy remote care monitoring program: integration of SMS text patient-reported outcomes in the electronic health record and pharmacist intervention for chemotherapy-induced nausea and vomiting.","volume":"17","author":"Hough","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"R8-20260519","first-page":"280","article-title":"2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients.","volume":"32","author":"Kennedy","year":"2024","journal-title":"Support Care Cancer"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.2147\/CMAR.S254398","article-title":"Efficacy of olanzapine-triple antiemetic regimen in patients with gastrointestinal tumor and high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: a retrospective study.","volume":"12","author":"Wu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"e35952","DOI":"10.1097\/MD.0000000000035952","article-title":"Efficacy and safety of aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: a meta-analysis.","volume":"102","author":"Zhang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1634\/theoncologist.2020-0305","article-title":"Metoclopramide, dexamethasone, or palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy (MEDEA): a randomized, phase III, noninferiority trial.","volume":"26","author":"van der Vorst","year":"2021","journal-title":"Oncologist"},{"key":"R12-20260519","first-page":"e44438","article-title":"Chemotherapy-induced nausea and vomiting in patients with breast cancer: risk factor and predictive model using classification and regression tree (CART).","volume":"15","author":"Ng","year":"2023","journal-title":"Cureus"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12885-021-07802-y","article-title":"Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.","volume":"21","author":"Hayashi","year":"2021","journal-title":"BMC Cancer"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"e70549","DOI":"10.1002\/cam4.70549","article-title":"NEPA (netupitant\/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy who experienced breakthrough CINV in cycle 1 of chemotherapy: a phase II clinical trial.","volume":"14","author":"Navari","year":"2025","journal-title":"Cancer Med"},{"key":"R15-20260519","first-page":"11","article-title":"Guidelines versus individualized care for the management of CINV.","volume":"26","author":"Clemons","year":"2018","journal-title":"Support Care Cancer"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s12885-023-11070-3","article-title":"Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy.","volume":"23","author":"Gao","year":"2023","journal-title":"BMC Cancer"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"e32116","DOI":"10.1097\/MD.0000000000032116","article-title":"The emerging role of olanzapine in paediatric CINV control: a review.","volume":"101","author":"Baru\u0161i\u0107","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1186\/s12885-021-08572-3","article-title":"Efficacy and safety of 5\u2009mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.","volume":"21","author":"Yamamoto","year":"2021","journal-title":"BMC Cancer"},{"key":"R19-20260519","first-page":"505","article-title":"Prevalence and predictors of long-delayed (>120\u2009h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.","volume":"31","author":"Chow","year":"2023","journal-title":"Support Care Cancer"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/00185787241231739","article-title":"Trial sequential analysis and meta-analysis of olanzapine in pediatric patients for chemotherapy-induced nausea and vomiting (CINV).","volume":"59","author":"Singh","year":"2024","journal-title":"Hosp Pharm"},{"key":"R21-20260519","first-page":"e1127","article-title":"Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey.","volume":"1","author":"Aapro","year":"2018","journal-title":"Cancer Rep (Hoboken)"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"e21559","DOI":"10.1097\/MD.0000000000021559","article-title":"Antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting: an updated systematic review and meta-analysis.","volume":"99","author":"Qiu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R23-20260519","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1002\/cam4.5962","article-title":"Acupuncture for the prevention of chemotherapy-induced nausea and vomiting in cancer patients: a systematic review and meta-analysis.","volume":"12","author":"Yan","year":"2023","journal-title":"Cancer Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:03:37Z","timestamp":1779195817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047389","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-04-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}